Therapeutic effect and safety of Nateglinide combined with Insulin Glargine in the treatment of type 2 diabetes patients with secondary sulphanyluteas drugs failure

Objective:To investigate the efficacy and safety of Nateglinide combined with Insulin Glargine in the treatment of type 2 diabetes patients with secondary sulfonylureas failure.Methods:Type 2 diabetes patients with secondary sulfonylureas failure were divided into two groups.The trial group was treated by Nateglinide with Insulin Glargine Injection.The control group was shifted to sulphanylureas drugs plus Glargine.Both groups were under treatment for three months with determining the fasting blood glucose(FBG),2 hour postprandial blood(2 h PG),glycosylated hemoglobin(HbA 1c) and C-peptide before and after the treatment as well as adverse reactions.Results:After treatment,the levels of FBG,2 h PG,and HbA1c in trial and control group decreased significantly compared with those before treatment(P0.05 or P0.01),but there was no significant difference in the decrease of FBG and HbA1c,increase of C-peptide,30 min C-peptide,120 min C-peptide between the two groups(P0.05).The 2 h PG and C-peptide in trial and control group decreased and raised significantly seperately(P0.05).The peak of C-peptide of trial group occurred 1 hour after meal and was higher than that of control group(P0.05),the peak of C-peptide of control group occurred 3 hours after meal and was higher than that of trial group(P0.05).The main adverse reaction was hypoglycemia,showing significant difference between the two groups(P0.05).Conclusion:Nateglinide combined with Insulin Glargine can control the blood glucose effectively in type 2 diabetes patients of secondary sulphanyluteas drugs failure with low incidence of hypoglycemia and high safety accompanied.